VIVUS Press Releases

Date Title Links
Toggle Summary VIVUS Announces Positive Phase 2 Clinical Trial Results With Qnexa, a Novel Therapy to Treat Obesity
Over 50% of Obese Patients Experienced 10% or More Total Body Weight Loss in a 24-Week Study
View HTML
Toggle Summary VIVUS to Raise $12 Million in Registered Direct Offering of Common Stock
Proceeds to Fund Clinical Advancement of the Qnexa Program for the Treatment of Obesity
View HTML
Toggle Summary VIVUS to Host Conference Call & Webcast on Wednesday, May 10th
VIVUS to Host Conference Call & Webcast on Wednesday, May 10th MOUNTAIN VIEW, Calif., May 9 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS), an emerging pharmaceutical company dedicated to the development and commercialization of novel therapeutics to restore sexual function in women and men,
View HTML
Toggle Summary VIVUS to Present at the Rodman & Renshaw 3rd Annual Global Healthcare Conference
VIVUS to Present at the Rodman & Renshaw 3rd Annual Global Healthcare Conference MOUNTAIN VIEW, Calif., May 8 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS), an emerging pharmaceutical company dedicated to the development and commercialization of novel therapeutics to restore sexual function
View HTML
Toggle Summary VIVUS Announces Positive Phase 3 Clinical Trial Results for Evamist(TM) - The First Transdermal Spray for the Treatment of Menopausal Symptoms
Evamist, First Novel Transdermal Spray, Shows 78% Decrease in Moderate to Severe Hot Flashes
View HTML
Toggle Summary VIVUS Reports First Quarter 2006 Financial Results and Product Development Highlights
VIVUS Reports First Quarter 2006 Financial Results and Product Development Highlights MOUNTAIN VIEW, Calif., April 27 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS), an emerging pharmaceutical company dedicated to the development and commercialization of novel therapeutics to restore sexual
View HTML
Toggle Summary VIVUS Announces First Quarter 2006 Financial Results Conference Call
VIVUS Announces First Quarter 2006 Financial Results Conference Call MOUNTAIN VIEW, Calif., April 21 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS), an emerging pharmaceutical company dedicated to the development and commercialization of novel therapeutics to restore sexual function in women
View HTML
Toggle Summary VIVUS to Present at Cowen & Co. 26th Annual Health Care Conference
VIVUS to Present at Cowen & Co. 26th Annual Health Care Conference MOUNTAIN VIEW, Calif., March 2 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS), a leading specialty pharmaceutical company focused on the development and commercialization of novel products to restore sexual function in women
View HTML
Toggle Summary VIVUS Announces Grant of Key Patent for MDTS® Delivery System
Evamist(TM) and Testosterone MDTS® Patent Life Extended to 2022
View HTML
Toggle Summary VIVUS Reports 2005 Fourth Quarter and Full-Year Financial Results
Multiple Late-Stage Product Candidates Continue to Meet Key Development Milestones
View HTML